Literature DB >> 15128473

Adding low-dose spironolactone to multidrug regimens for resistant hypertension.

Kathleen H Berecek1, Amal Farag, Gul Bahtiyar, Jeffery Rothman, Sammy I McFarlane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15128473

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  14 in total

1.  Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.

Authors:  A Sato; T Saruta
Journal:  J Int Med Res       Date:  2001 Jan-Feb       Impact factor: 1.671

Review 2.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  J I Barzilay; C L Jones; B R Davis; J N Basile; D C Goff; J O Ciocon; M E Sweeney; O S Randall
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

5.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.

Authors:  J Staessen; P Lijnen; R Fagard; L J Verschueren; A Amery
Journal:  J Endocrinol       Date:  1981-12       Impact factor: 4.286

6.  [Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn's syndrome (author's transl)].

Authors:  G Wambach; A Helber; G Bönner; W Hummerich; K A Meurer; W Kaufmann
Journal:  Dtsch Med Wochenschr       Date:  1980-05-02       Impact factor: 0.628

7.  Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.

Authors:  H Schepkens; R Vanholder; J M Billiouw; N Lameire
Journal:  Am J Med       Date:  2001-04-15       Impact factor: 4.965

Review 8.  Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity.

Authors:  P O Lim; R T Jung; T M MacDonald
Journal:  J Hum Hypertens       Date:  2002-03       Impact factor: 3.012

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Renin concentrations and effects of propranolol and spironolactone in patients with hypertension.

Authors:  B E Karlberg; B Kågedal; L Tegler; K Tolagen
Journal:  Br Med J       Date:  1976-01-31
View more
  2 in total

1.  Resistant hypertension optimal treatment trial: a randomized controlled trial.

Authors:  Eduardo M Krieger; Luciano F Drager; Dante Marcelo Artigas Giorgi; Jose Eduardo Krieger; Alexandre Costa Pereira; José Augusto Soares Barreto-Filho; Armando da Rocha Nogueira; José Geraldo Mill
Journal:  Clin Cardiol       Date:  2013-12-11       Impact factor: 2.882

2.  Role of Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Orlistat based Multidrug Therapy in Glycemic Control, Weight Loss, and Euglycemia in Diabesity: A Real-World Experience.

Authors:  Deep Dutta; Ritu Jaisani; Deepak Khandelwal; Soumitra Ghosh; Rajiv Malhotra; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2019 Jul-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.